Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2013 Jan 8;16(2):10.1038/pcan.2012.49. doi: 10.1038/pcan.2012.49

Figure 6.

Figure 6

Combination therapy to overcome tumor heterogeneity. (a) Shows a schematic representation of our experimental design to test the efficacy of combination (Flutamide +CAR-Muc1 T cells) therapy in vitro. (b) To evaluate whether combination therapy would produce superior anti-tumor effects LNCaP cells were left untreated or treated with Flutamide alone, CAR-Muc1 T cells alone or the combination (1:2). After co-culture for 72 h (ratio 1 tumor cell:2 T cells) residual tumor cell numbers were evaluated and total residual cell numbers are reported. Data represent the mean±s.d. of four donors.